Reviews - 3hll mentioned but not cited (1)
- Chiral kinase inhibitors. Jiang JK, Shen M, Thomas CJ, Boxer MB. Curr Top Med Chem 11 800-809 (2011)
Articles - 3hll mentioned but not cited (2)
- Structure-based predictions of activity cliffs. Husby J, Bottegoni G, Kufareva I, Abagyan R, Cavalli A. J Chem Inf Model 55 1062-1076 (2015)
- p38α Mitogen-Activated Protein Kinase Is a Druggable Target in Pancreatic Adenocarcinoma. Yang L, Sun X, Ye Y, Lu Y, Zuo J, Liu W, Elcock A, Zhu S. Front Oncol 9 1294 (2019)
Reviews citing this publication (6)
- Mechanisms and functions of p38 MAPK signalling. Cuadrado A, Nebreda AR. Biochem. J. 429 403-417 (2010)
- p38 mitogen-activated protein kinase pathways in asthma and COPD. Chung KF. Chest 139 1470-1479 (2011)
- p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011). Fischer S, Koeberle SC, Laufer SA. Expert Opin Ther Pat 21 1843-1866 (2011)
- p38 Mitogen activated protein kinase (MAPK): a new therapeutic target for reducing the risk of adverse pregnancy outcomes. Menon R, Papaconstantinou J. Expert Opin. Ther. Targets 20 1397-1412 (2016)
- A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors. Astolfi A, Iraci N, Manfroni G, Barreca ML, Cecchetti V. ChemMedChem 10 957-969 (2015)
- Atypical p38 Signaling, Activation, and Implications for Disease. Burton JC, Antoniades W, Okalova J, Roos MM, Grimsey NJ. Int J Mol Sci 22 4183 (2021)
Articles citing this publication (17)
- Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. Pereira L, Igea A, Canovas B, Dolado I, Nebreda AR. EMBO Mol Med 5 1759-1774 (2013)
- Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Huang D, Zhou T, Lafleur K, Nevado C, Caflisch A. Bioinformatics 26 198-204 (2010)
- Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. Watterson DM, Grum-Tokars VL, Roy SM, Schavocky JP, Bradaric BD, Bachstetter AD, Xing B, Dimayuga E, Saeed F, Zhang H, Staniszewski A, Pelletier JC, Minasov G, Anderson WF, Arancio O, Van Eldik LJ. PLoS ONE 8 e66226 (2013)
- Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, Saabye MJ, Schindler JF, Selness SR, Stillwell LI, Webb EG, Zhang J, Monahan JB. J Pharmacol Exp Ther 331 882-895 (2009)
- Apoptosis Signal-regulating Kinase 1 (ASK1)-p38 Pathway-dependent Cytoplasmic Translocation of the Orphan Nuclear Receptor NR4A2 Is Required for Oxidative Stress-induced Necrosis. Watanabe T, Sekine S, Naguro I, Sekine Y, Ichijo H. J. Biol. Chem. 290 10791-10803 (2015)
- Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate. Xing L, Devadas B, Devraj RV, Selness SR, Shieh H, Walker JK, Mao M, Messing D, Samas B, Yang JZ, Anderson GD, Webb EG, Monahan JB. ChemMedChem 7 273-280 (2012)
- Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. Selness SR, Devraj RV, Devadas B, Walker JK, Boehm TL, Durley RC, Shieh H, Xing L, Rucker PV, Jerome KD, Benson AG, Marrufo LD, Madsen HM, Hitchcock J, Owen TJ, Christie L, Promo MA, Hickory BS, Alvira E, Naing W, Blevis-Bal R, Messing D, Yang J, Mao MK, Yalamanchili G, Vonder Embse R, Hirsch J, Saabye M, Bonar S, Webb E, Anderson G, Monahan JB. Bioorg. Med. Chem. Lett. 21 4066-4071 (2011)
- X-ray structure of p38α bound to TAK-715: comparison with three classic inhibitors. Azevedo R, van Zeeland M, Raaijmakers H, Kazemier B, de Vlieg J, Oubrie A. Acta Crystallogr. D Biol. Crystallogr. 68 1041-1050 (2012)
- Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation. Kusakabe K, Ide N, Daigo Y, Itoh T, Higashino K, Okano Y, Tadano G, Tachibana Y, Sato Y, Inoue M, Wada T, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Tagashira S, Kido Y, Sakamoto S, Yasuo K, Maeda M, Yamamoto T, Higaki M, Endoh T, Ueda K, Shiota T, Murai H, Nakamura Y. ACS Med Chem Lett 3 560-564 (2012)
- Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors. Devadas B, Selness SR, Xing L, Madsen HM, Marrufo LD, Shieh H, Messing DM, Yang JZ, Morgan HM, Anderson GD, Webb EG, Zhang J, Devraj RV, Monahan JB. Bioorg. Med. Chem. Lett. 21 3856-3860 (2011)
- Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept. Hasumi K, Sato S, Saito T, Kato JY, Shirota K, Sato J, Suzuki H, Ohta S. Bioorg. Med. Chem. 22 4162-4176 (2014)
- Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition. Jerome KD, Rucker PV, Xing L, Shieh HS, Baldus JE, Selness SR, Letavic MA, Braganza JF, McClure KF. Bioorg. Med. Chem. Lett. 20 469-473 (2010)
- Integrating targeted gene expression and a skin model system to identify functional inhibitors of the UV activated p38 MAP kinase. Abrahams A, Mouchet N, Gouault N, Lohézic Le Dévéhat F, Le Roch M, Rouaud I, Gilot D, Galibert MD. Photochem. Photobiol. Sci. 15 1468-1475 (2016)
- A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia. Arriazu E, Vicente C, Pippa R, Peris I, Martínez-Balsalobre E, García-Ramírez P, Marcotegui N, Igea A, Alignani D, Rifón J, Mateos MC, Cayuela ML, Nebreda AR, Odero MD. Blood Cancer J 10 3 (2020)
- High-throughput screen to identify compounds that prevent or target telomere loss in human cancer cells. Wilson C, Murnane JP. NAR Cancer 4 zcac029 (2022)
- How many kinases are druggable? A review of our current understanding. Anderson B, Rosston P, Ong HW, Hossain MA, Davis-Gilbert ZW, Drewry DH. Biochem J 480 1331-1363 (2023)
- Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration. Chaudhary O, Narayan V, Lelis F, Linz B, Watkins M, Veazey R, Aldovini A. PLoS Pathog. 14 e1007268 (2018)